Endometrial intraepithelial neoplasia risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Endometrial intraepithelial neoplasia}} | {{Endometrial intraepithelial neoplasia}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
==Risk Factors== | |||
Risk factors for development of EIN and the endometrioid type of endometrial carcinoma include exposure to estrogens without opposing progestins, obesity, diabetes, and rare hereditary conditions such as [[hereditary nonpolyposis colorectal cancer]]. Protective factors include use of [[combined oral contraceptive pills]] (low dose estrogen and progestin), and prior use of a contraceptive [[intrauterine device]]. | Risk factors for development of EIN and the endometrioid type of endometrial carcinoma include exposure to estrogens without opposing progestins, obesity, diabetes, and rare hereditary conditions such as [[hereditary nonpolyposis colorectal cancer]]. Protective factors include use of [[combined oral contraceptive pills]] (low dose estrogen and progestin), and prior use of a contraceptive [[intrauterine device]]. | ||
| Line 10: | Line 12: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Gynecology]] | [[Category:Gynecology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 20:01, 20 August 2015
Template:Endometrial intraepithelial neoplasia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Risk Factors
Risk factors for development of EIN and the endometrioid type of endometrial carcinoma include exposure to estrogens without opposing progestins, obesity, diabetes, and rare hereditary conditions such as hereditary nonpolyposis colorectal cancer. Protective factors include use of combined oral contraceptive pills (low dose estrogen and progestin), and prior use of a contraceptive intrauterine device.